AAIPharma, a provider of pharmaceutical product development services, is acquiring a materials testing services firm.
The Wilmington-based company said Wednesday it had bought Celsis Analytical Services, which is part of Celsis International. The group focuses on materials for pharma, biotech and manufacturing firms.
Financial terms were not disclosed.
“The addition of Celsis Analytical Services will enable AAIPharma to expand its market presence in two key regions,” said Patrick Walsh, CEO of AAIPharma, in a statement. “Our combined company will bring a differentiated offering to the contract services market with an integrated development and material testing service mode.”
The Celis group operates labs of 65,000 square feet in size in New Jersey and St. Louis.
AAIPharma has 300,000 square feet of facilities already in operation.
“The combined entity offers a comprehensive menu of methods validation and testing services for biotechnology, pharmaceutical and consumer products manufacturers, raw materials suppliers and manufacturers of agricultural and veterinary medicine products,” the company said.
The acquisition is the latest expansion undertaken by AAIPharma under the ownership of Water Street Healthcare Partners, a private equity firm which acquired the company in 2009.
Last week, AAIPharma said its revenues grew by 9 percent from the previous quarter to a new high under Water Street ownership.
AAIPharma alsom is expanding its facilities in Wilmington and in Charleston, S.C. A 40,000 square foot lab and tech center is being built at its Wilmington headquarters.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.
